Quinidine Antibody (501): sc-57990

Quinidine Antibody (501) is a mouse monoclonal IgG2b antibody that detects Quinidine protein in non-species reactive applications by enzyme-linked immunosorbent assay (ELISA). Anti-Quinidine antibody (501) is available as a non-conjugated isotype antibody. Quinidine, a class I antiarrhythmic agent derived from the bark of the cinchona tree, plays a crucial role in managing cardiac arrhythmias by blocking fast inward sodium currents, which decreases the phase 0 depolarization of the cardiac action potential and prolongs both the action potential duration and the QT interval on the electrocardiogram. This modulation of cardiac electrical activity is vital for restoring normal heart rhythm and preventing potentially life-threatening arrhythmias. Additionally, Quinidine interacts with various ion channels, including the tetrodotoxin-sensitive sodium current and calcium currents, as well as multiple potassium currents, which further underscores its importance in cardiac electrophysiology. The ability of Quinidine to inhibit cytochrome P450 enzyme 2D6 is also significant, as it can lead to increased plasma levels of other medications, such as lidocaine and certain beta blockers, necessitating careful monitoring during co-administration. With a half-life of six to eight hours and a molecular weight of 324.417 g/mol, Quinidine is primarily metabolized in the liver, highlighting the importance of understanding its pharmacokinetics for effective therapeutic use.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Quinidine Antibody (501) References:

1. Sympathetic activation enhances QT prolongation by quinidine.  |  Darbar, D., et al. 2001. J Cardiovasc Electrophysiol. 12: 9-14. PMID: 11204091
2. Serum quinidine concentrations and effect on QT dispersion and interval.  |  Mathis, AS. and Gandhi, AJ. 2002. Ann Pharmacother. 36: 1156-61. PMID: 12086546
3. Ethanol excitation of dopaminergic ventral tegmental area neurons is blocked by quinidine.  |  Appel, SB., et al. 2003. J Pharmacol Exp Ther. 306: 437-46. PMID: 12721326
4. Mechanism of action of quinidine on squid axon membranes.  |  Yeh, JZ. and Narahashi, T. 1976. J Pharmacol Exp Ther. 196: 62-70. PMID: 1518
5. Quinidine blocks adenosine 5'-triphosphate-sensitive potassium channels in heart.  |  Undrovinas, AI., et al. 1990. Am J Physiol. 259: H1609-12. PMID: 2240258
6. Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes.  |  Salata, JJ. and Wasserstrom, JA. 1988. Circ Res. 62: 324-37. PMID: 2448058
7. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.  |  von Moltke, LL., et al. 1994. Br J Clin Pharmacol. 38: 23-31. PMID: 7946933
8. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms.  |  Nattel, S. and Quantz, MA. 1988. Cardiovasc Res. 22: 808-17. PMID: 3256422
9. Effects of quinidine on repolarization in canine epicardium, midmyocardium, and endocardium: II. In vivo study.  |  Anyukhovsky, EP., et al. 1997. Circulation. 96: 4019-26. PMID: 9403627